Target intelligence / Profile preview

Cystatin-SN (CST1)

Target
CST1
Molecular classification
Cysteine proteinase inhibitor, Type 2 cystatin, Proteinase inhibitor, Member of cystatin superfamily
01

Overview

Cystatin-SN (CST1) is a type 2 cystatin, a member of the cystatin superfamily of cysteine proteinase inhibitors, encoded by the CST1 gene on human chromosome 20. CST1 is secreted in various bodily fluids including saliva, tears, urine, and seminal fluid, and primarily inhibits cysteine proteases such as papain and dipeptidyl peptidase I, contributing to the regulation of extracellular proteolysis. CST1 forms tight complexes with its target enzymes to block inappropriate tissue degradation and may play a protective role in antimicrobial defense. Elevated CST1 expression is associated with increased proliferation and metastasis in colorectal and gastric cancers, likely due to its regulatory interaction with other protease inhibitors such as CST3 (cystatin C), which shifts the balance of protease activity in favor of tumor invasion.

Other names
Cystatin-SNCST1Cystain-SA-ICystatin-1Salivary cystatin-SA-1Cystatin SA-ICysteine proteinase inhibitor, type 2 familyCystatin SNCystein proteinase inhibitor, type 2 family
02

Mechanism of action

Protease inhibition: drugs could modulate CST1's interaction with cysteine proteases or its regulatory effect on protease activity (e.g., cathepsins). Interference with CST1/CST3/CTSB interactions to inhibit tumor cell invasion.

03

Biological functions

Inhibition of cysteine proteases (especially papain, dipeptidyl peptidase I)Formation of tight equimolar complexes with proteases, limiting inappropriate tissue proteolysisExtracellular protease regulationPossible protective roles in antibacterial and antiviral processes
04

Disease associations

Cancer (upregulated in colorectal and gastric cancer, involved in tumor growth and metastasis)Dental cariesDenture stomatitisOther (likely related to protease imbalance, tissue invasion/metastasis)
05

Safety considerations

Therapeutic targeting could disrupt necessary protease inhibition, leading to unintended tissue damage, impaired immune response, or homeostatic disruption.Specific adverse effects are not described due to lack of clinical drugs.
06

Biomarkers

CST1 upregulation in tumor tissues (especially colorectal and gastric) may serve as a biomarker for disease progression and metastasis

Beyond the preview

Go deeper on Cystatin-SN (CST1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cystatin-SN (CST1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call